Major facilities
Our principal executive offices are located in Basel, Switzerland. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.
We generally own our facilities or have entered into long-term lease arrangements for them. Some of our principal facilities are subject to mortgages and other security interests granted to secure indebtedness to certain financial institutions.
NTO manages the production and supply chains of our Innovative Medicines and Sandoz Division products through a network of 60 manufacturing sites, as well as through external suppliers, and warehouse and distribution centers. AAA manages four sites for radioligand therapies production, and certain other small sites for diagnostics and enriched water production. Novartis Gene Therapies manages six sites for research and development, production, warehousing, its headquarters and administrative offices. Endocyte manages two sites for research and its headquarters and administrative offices.
The following table sets forth our major headquarters and most significant production, research and development, and administrative facilities.
| Basel, Switzerland – St. Johann | Global Group headquarters; global Innovative Medicines Division headquarters; Global Sandoz Division; research and development; production of drug substances and drug intermediates |
| Kundl and Schaftenau, Austria | Production of biotechnological products, drug products and finished products, anti‑infectives, active drug substances, product development |
| East Hanover, New Jersey, USA | Innovative Medicines Division US headquarters, research and development |
| Barleben, Germany | Production of broad range of generics finished dosage forms |
| Cambridge, Massachusetts, USA | Research and development |
| Shanghai, China | Research and development |
| Ljubljana, Slovenia | Production of broad range of finished solid and sterile dosage forms |
| Hyderabad, India | General administrative and development global service center |
| Longmont, Colorado, USA | Production, warehouse, and administrative offices for Novartis Gene Therapies |
| Stein, Switzerland | Production of sterile vials, pre‑filled syringes and ampoules; inhalation capsules, tablets and transdermals; active pharmaceutical ingredients, and cell and gene therapies |
| Holzkirchen, Germany | Global Sandoz Division headquarters, production of oral films, transdermal delivery systems, matrix patches, product development |
| Menges, Slovenia | Production of drug substances and drug intermediates |
| Strykow, Poland | Production of broad range of bulk oral solid forms and packaging |
| Huningue, France | Production of drug substances for clinical and commercial supply |
| Singapore | Production for Innovative Medicines solids and biologics |
| Barbera, Spain | Production of tablets, capsules and inhalation products |
| Basel – Schweizerhalle, Switzerland | Production of drug substances and drug intermediates |
| Ruell-Malmaison, France | Administrative offices for Innovative Medicines |
| Puurs, Belgium | Production for Innovative Medicines ophthalmic products |
| Tokyo, Japan | Administrative offices for Innovative Medicines and Sandoz |
| Morris Plains, New Jersey, USA | Production for Innovative Medicines Division cell and gene therapies |
| Princeton, New Jersey, USA | Sandoz Division US headquarters |
| Libertyville, Illinois, USA | Production, warehouse, and administrative offices for Novartis Gene Therapies |
| Targu Mures, Romania | Production of solids for Innovative Medicines and Sandoz |
| Les Ulis, France | Production for Innovative Medicines Division cell and gene therapies |
| Millburn, New Jersey, USA | AAA primary production site for radioligand therapy |
| Colleretto Giacosa/Ivrea, Italy | AAA primary production site for radioligand therapy |
| San Diego, California, USA | Research and early development for Novartis Gene Therapies |
| Durham, North Carolina, USA | Production, warehouse, and administrative offices for Novartis Gene Therapies |
Disclaimer:
These materials contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the impact of the COVID-19 pandemic on certain therapeutic areas including dermatology, ophthalmology and the Sandoz retail business, and on drug development operations; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group’s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding our collaboration with the African Union to supply medicines for treatment of COVID-19. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics, particularly in ophthalmology, in the fourth quarter of 2020; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in these materials; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in these materials as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.